NBA Won’t Suspend Dirty Zaza Pachulia For Piling On Russell Westbrook
The talk of the NBA has been the illegal wrestling move Golden State's Zaza Pachulia inflicted on Oklahoma City's Russell Westbrook in Saturday night's...
GE Hit By Earnings Restatements
Per Reuters General Electric (GE) will restate two years of earnings:
General Electric (GE.N), the United States’ largest industrial conglomerate, will restate its earnings for...
Deandre Ayton’s Lawyer Echoes Sergeant Schultz – ‘I Know Nothing’
Payments by college sports teams to players have been going on for years. The FBI wants to put a spotlight on it and the...
Dirty ZaZa Tried To Break Russell Westbrook’s Kneecaps
The Golden State Warriors took on the Oklahoma City Thunder Saturday night and the game was as entertaining as expected. Kevin Durant left OKC...
FBI Wiretap Shows Sean Miller Discussed $100K Payment To Deandre Ayton
College basketball has dominated the news cycle over the past six months and has not been for anything positive. Former Louisville basketball coach Rick...
Can Valeant Bulls Stomach Double-Digit Revenue Declines?
Valeant (VRX) reports Q4 earnings February 28th. Analysts expect revenue of $2.17 billion and eps of $0.98. The revenue estimate implies a 2% decline...
Patent Office Puts Allergan’s Mohawk Deal Out Of Its Misery
In a much-anticipated ruling the Patent Trial And Appeal Board ("PTAB") of the U.S. Patent And Trademark Office ruled the St. Regis Mohawk Tribe...
Teva: Berkshire Thinks Bondholders Are ‘Mullet Money’; Think Again
Teva (TEVA) has been reeling since Mylan's (MYL) generic Copaxone was approved Q4 2017. Having one's most-profitable drug go generic is never a good...
Teva, Allergan Patent Fight Could Sound The Death Knell For Mallinckrodt
Mallinckrodt (MNK) is in dire straits. Management built the company on a string of pharmaceutical acquisitions. Post-deal management would raise prices of the acquired...
Allergan: Europe Halts Esmya Prescriptions Due To Liver Risk
Earlier this month the European Medicines Agency ("EMA") advised that no new patients take Esmya while the agency reviews the drug for possible links...
